EDWARDS LIFESCIENCES LLC — Lobbying Disclosure | Poliscope

EDWARDS LIFESCIENCES LLC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$25.9M

Filings

219

Firms Hired

Active Period

2005–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$920,000	12	4
2025	$1,340,000	16	4
2024	$1,550,000	17	4
2023	$1,940,000	17	4
2022	$1,250,000	16	4
2021	$1,110,000	17	4
2020	$1,920,000	14	3
2019	$1,660,000	16	4
2018	$1,960,000	19	4
2017	$1,280,000	11	2
2016	$1,130,000	5	1
2015	$1,000,000	4	1
2014	$890,000	4	1
2013	$1,090,000	5	2
2012	$1,150,000	8	2
2011	$1,090,000	9	2
2010	$990,000	4	1
2009	$1,377,127	5	1
2008	$1,600,598	9	1
2007	$304,558	4	1
2006	$192,341	2	1
2005	$159,587	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
EDWARDS LIFESCIENCES LLC	$25,904,212	101
BGR GOVERNMENT AFFAIRS	—	35
FARRAGUT PARTNERS LLP	—	42
AVENUE SOLUTIONS	—	23
CAUTHEN FORBES & WILLIAMS	—	10
CAPITOL COUNSEL LLC	—	8

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	198
SENATE	194
Centers For Medicare and Medicaid Services (CMS)	97
Health & Human Services, Dept of (HHS)	86
Food & Drug Administration (FDA)	79
Treasury, Dept of	21
Executive Office of the President (EOP)	9
White House Office	9
U.S. Trade Representative (USTR)	6
Commerce, Dept of (DOC)	5
Office of Management & Budget (OMB)	2
Transportation, Dept of (DOT)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	181
Health Issues	Health Issues	175
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	87
Trade (domestic/foreign)	Trade (domestic/foreign)	48
Clean Air and Water (quality)	Clean Air and Water (quality)	23
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	22
Copyright/Patent/Trademark	Copyright/Patent/Trademark	18
Budget/Appropriations	Budget/Appropriations	13
Agriculture	Agriculture	8
Veterans	Veterans	7
Torts	Torts	6
Manufacturing	Manufacturing	4
Science/Technology	Science/Technology	2
Transportation	Transportation	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · third_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5343

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · third_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Client expense: — · Firm income: $50,000

Matched citations: S. 1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · third_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

Client expense: $300,000 · Firm income: —

Matched citations: H.R.5343

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · third_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development

Client expense: $300,000 · Firm income: —

Matched citations: H.R.5343

Show 21 more cited filings

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · third_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development

Client expense: $300,000 · Firm income: —

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · third_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

Client expense: $300,000 · Firm income: —

Matched citations: S.1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · second_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development

Client expense: $280,000 · Firm income: —

Matched citations: H.R.5343

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · second_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

Client expense: $280,000 · Firm income: —

Matched citations: H.R.5343

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · second_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development

Client expense: $280,000 · Firm income: —

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · second_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

Client expense: $280,000 · Firm income: —

Matched citations: S.1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · second_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5343

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · second_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to CMSs draft coverage policy for transcatheter aortic valve replacement (TAVR) issued June 15, 2026; Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Issues related to Senate Finance Dear Colleague process

Client expense: — · Firm income: $50,000

Matched citations: S. 1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · first_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5343

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · first_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process

Client expense: — · Firm income: $50,000

Matched citations: S. 1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · first_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development

Client expense: $340,000 · Firm income: —

Matched citations: H.R.5343

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2026 · first_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development

Client expense: $340,000 · Firm income: —

Matched citations: H.R.5343

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · first_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development

Client expense: $340,000 · Firm income: —

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2026 · first_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development

Client expense: $340,000 · Firm income: —

Matched citations: S.1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2025 · fourth_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Client expense: $350,000 · Firm income: —

Matched citations: H.R. 5343

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2025 · fourth_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials

Client expense: $350,000 · Firm income: —

Matched citations: H.R. 5343

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2025 · fourth_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials

Client expense: $350,000 · Firm income: —

Matched citations: S.1717

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2025 · fourth_quarter · Firm: EDWARDS LIFESCIENCES LLC

Open original LDA filing ↗

Cited source text and reported amounts

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Client expense: $350,000 · Firm income: —

Matched citations: S.1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2025 · fourth_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5343

S. 1717119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

2025 · fourth_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders

Client expense: — · Firm income: $50,000

Matched citations: S. 1717

H.R. 5343119th Congress

Ensuring Patient Access to Critical Breakthrough Products Act

2025 · third_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5343

Source: Senate LDA